Skip to main content
OpenTrials
Completed

NCT Number: NCT02731521

Clinical Development of MR Spectroscopy and Imaging in Brain Cancers

The Investigators will examine the disease specificity of 2-hydroxyglutarate in non-glioma brain lesions, and the clinical utility of 2-hydroxyglutarate, glycine and citrate in isocitrate dehydrogenase (IDH) mutated gliomas and IDH wild type gliomas.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

UT Southwestern Medical Center

Dallas, Texas, 75390, United States

About this study

2-hydroxyglutarate (2HG) imaging will identify glioma, tumor progression and response to therapy noninvasively at an earlier time point than currently detectable with standard MR imaging. This utility of 2HG can be used for improving the patient care in a more effective manner when the 2HG imaging is incorporated in regular clinical MR scans in brain tumor patients. We aim to translate the 2HG MRS protocol into two clinical MR centers at UTSouthwestern Medical Center: The Mary Nell and Ralph B. Rogers Magnetic Resonance Center with Philips 1.5Tesla and 3Tesla scanners and The Algur H. Meadows Diagnostic Imaging Center with a GE 3Tesla scanner. In addition, we will perform Magnetic Resonance (MR) scans in patients with neurological diseases that can mimic gliomas, including stroke, epilepsy, encephalitis, and brain metastases in order to establish the specificity of 2HG to malignant gliomas.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(120 Brain Tumor Patients)

  • All races and ethnicities
  • Must meet at least one of the 3 following criteria regarding diagnosis:
  • Histological diagnosis of a brain tumor
  • Pre-operative MR imaging suggestive of a brain tumor
  • Radiographic diagnosis of brain tumor in an inoperable location (e.g. brainstem)
  • Pretreatment evaluations required for eligibility include a medical history, physical examination, and neurological exam within 30 days prior to study entry.
  • Patient must be able to provide study-specific consent prior to study entry and Health Insurance Portability and Accountability Act of 1996 (HIPAA) authorization.
  • Karnofsky performance status >70%
  • Life expectancy greater than 3 months.

(50 Non-Tumor Neurological Disorders)

  • All races and ethnicities
  • Patients with clinically-proven multiple sclerosis, temporal lobe epilepsy, stroke, or encephalitis.

(5 Health Volunteers)

  • 18-40 years of age
  • All races and ethnicities
  • Excellent general health

Exclusion criteria

  • Under age 18
  • Cardiac pacemaker
  • Intracranial clips, metal implants, or external clips within 50 cm from the head
  • Metal in eye
  • Pregnancy
  • Claustrophobia
  • Obesity or any other factors that provide difficulty with supine pose in the magnet
  • Patients who are unable to provide informed consent
  • Patients who are pregnant or nursing
  • Patients with severe kidney dysfunction or uncontrolled cardiac dysfunction
  • Patients who are claustrophobic or have other contraindication to MRI, such as implanted pacemaker device, vascular clips, surgical clips, prosthetic valves, pace¬makers, otologic implants
  • Patients with uncontrolled psychiatric manifestations of their brain tumor
  • Patients for 7 Tesla scans can have no metal in the body

Treatment and study plan

3 Tesla Scanning

Device

Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.

Other names: 3T MRI/MRS

7 Tesla Scanning

Device

Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.

Other names: 7T MRI/MRS

Primary outcomes

  1. Amount of 2-hydroxyglutarate (2HG) bio-marker in 170 patients with clinically-proven brain metastasis, multiple sclerosis, epilepsy, stroke, or encephalitis using magnetic resonance spectroscopy (MRS).

    Time frame: 1-4 scans, average over 36 months

    Measuring amount of 2-hydroxygluterate (2HG) biomarker with MRS.

Sponsors and collaborators

Lead sponsor

University of Texas Southwestern Medical Center

Other

Collaborators

  • Cancer Prevention Research Institute of Texas

Registry information

Important dates

Study start
2014
Primary completion
2021
Study completion
2021
First posted
Apr 7, 2016
Registry last updated
Feb 3, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.